China, United States

Latham, O'Melveny Help Ink Chinese Buy of U.S. Company

Deal will likely lead to more Chinese investment in U.S. companies, attorneys for both sides say

, The Asian Lawyer

   | 0 Comments

Chinese genome research and sequencing company BGI-Shenzhen has finalized its $117 million purchase of genome sequencing company Complete Genomics, marking the first acquisition of a U.S. public company by a Chinese acquirer. O'Melveny & Myers advised BGI; Latham & Watkins advised Complete Genomics.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202592931779

Thank you!

This article's comments will be reviewed.